ASX ANNOUNCEMENT
2 March 2010
BNC210 Clinical Trial Results Confirm Safety and Indicate Reduced
Stress Hormone Levels
BNC210 reduced blood levels of stress hormone in trial subjects,
indicating anxiolytic activity
Stage 2 of trial confirms BNC210 is safe and well tolerated
Supports potential for once a day oral administration of BNC210
Add to My Watchlist
What is My Watchlist?